Carregant...

A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma

Both the amplification of the gene coding for wild-type (wt) epidermal growth factor receptor (EGFR) and the overexpression of the EGFR deletion mutant, commonly known as EGFRvIII, are hallmarks of glioblastoma. We have recently reported a novel, recombinant immunotoxin, D2C7-(scdsFv)-PE38KDEL, that...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Chandramohan, Vidyalakshmi, Bigner, Darell D
Format: Artigo
Idioma:Inglês
Publicat: Landes Bioscience 2013
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3912004/
https://ncbi.nlm.nih.gov/pubmed/24498557
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/onci.26852
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!